156 results about "Blood proteins" patented technology

Compositions containing one or more types of membrane-targeting antimicrobial agents immobilized on a substrate with activity in relevant biological environments, and methods of making and using thereof, are described herein. The antimicrobial agents retain their activity in the presence of blood proteins and / or in vivo due to improved molecular structures which allow for cooperative action of immobilized agents and hydrophilic chemistries which resist non-specific protein adsorption. Suitable molecular structures include branched structures, such as dendrimers and randomly branched polymers. The molecule structures may also include hydrophilic tethers which provide both flexibility and resistance to non-specific protein adsorption. The membrane targeting antimicrobial agent coatings can be applied to a variety of different types of substrates including medical implants such as vascular grafts, orthopedic devices, dialysis access grafts, and catheters; surgical tools, surgical garments; and bandages. The substrates can be composed of metallic materials, ceramics, polymers, fibers, inert materials such as silicon, and combinations thereof. The compositions described herein are substantially non-leaching, resistant to non-specific protein adsorption, and non-hemolytic.

The present invention provides an array for rapidly identifying a host cell population capable of producing heterologous protein with improved yield and / or quality. The array comprises one or more host cell populations that have been genetically modified to increase the expression of one or more target genes involved in protein production, decrease the expression of one or more target genes involved in protein degradation, or both. One or more of the strains in the array may express the heterologous protein of interest in a periplasm compartment, or may secrete the heterologous protein extracellularly through an outer cell wall. The strain arrays are useful for screening for improved expression of any protein of interest, including therapeutic proteins, hormones, a growth factors, extracellular receptors or ligands, proteases, kinases, blood proteins, chemokines, cytokines, antibodies and the like.

This invention relates to coating a surface wherein the coated surface inhibits foulants such as cell and / or protein and / or prion adhesion or formation. In particular, the coated surface may be part of a medical device which inhibits bacterial adhesion and colonisation, thrombus formation and / or prion, blood protein and / or protein formation.

The present invention provides an array for rapidly identifying a host cell population capable of producing heterologous protein with improved yield and / or quality. The array comprises one or more host cell populations that have been genetically modified to increase the expression of one or more target genes involved in protein production, decrease the expression of one or more target genes involved in protein degradation, or both. One or more of the strains in the array may express the heterologous protein of interest in a periplasm compartment, or may secrete the heterologous protein extracellularly through an outer cell wall. The strain arrays are useful for screening for improved expression of any protein of interest, including therapeutic proteins, hormones, a growth factors, extracellular receptors or ligands, proteases, kinases, blood proteins, chemokines, cytokines, antibodies and the like.

The present invention provides an array for rapidly identifying a host cell population capable of producing a heterologous protein with improved yield and / or quality. The array comprises one or more host cell populations that have been genetically modified to increase the expression of one or more target genes involved in protein production, decrease the expression of one or more target genes involved in protein degradation, or both. One or more of the strains in the array may express the heterologous protein of interest in a periplasm compartment or may secrete the heterologous protein extracellularly through an outer cell wall. The strain arrays are useful for screening for improved expression of any protein of interest including therapeutic proteins, hormones, growth factors, extracellular receptors or ligands, proteases, kinases, blood proteins, chemokines, cytokines, antibodies and the like.

The invention is directed to blood proteins produced in monocot seeds and isolated therefrom for use in therapeutic compositions, and to methods of making these isolated blood proteins and to therapeutic compositions comprising them.

The invention relates to a compound feed for improving red drum flavor and a preparation method thereof. The compound feed comprises fishmeal, high-gluten flour, soy protein concentrate, fermented peanut meal, beer yeast, corn meal, fish oil, vegetable oil, squid paste, soy lecithin, blood protein powder, binder carboxymethyl cellulose, composite vitamins, composite minerals, choline chloride, betaine, carnitine, sodium dehydroacetate, and butyl hydroxy anisole. The compound feed of the invention has advantages of good attractant effect, good palatability, high feed utilization rate, good-quality red drum. The compound feed can better prevent a feed from oxidative deterioration, improves the feed utilization rate, improves red drum growth, reduces environmental pollution and has a significant environment-protection effect.

Modified anti-angiogenic peptides are disclosed. The modified peptides are capable of forming a peptidase stabilized anti-angiogenic peptide. The modified anti-angiogenic peptides, particularly modified kringle 5 peptides are capable of forming a conjugate with a blood protein. Conjugates are prepared from anti-angiogenic peptides, particularly kringle 5 peptides, by combining the peptide with a reactive functional group with a blood protein. The conjugates may be formed in vivo or ex vivo. The conjugates are administered to patients to provide an anti-angiogenic effect.

Modified anti-angiogenic peptides are disclosed. The modified peptides are capable of forming a peptidase stabilized anti-angiogenic peptide. The modified anti-angiogenic peptides, particularly modified kringle 5 peptides are capable of forming a conjugate with a blood protein. Conjugates are prepared from anti-angiogenic peptides, particularly kringle 5 peptides, by combining the peptide with a reactive functional group with a blood protein. The conjugates may be formed in vivo or ex vivo. The conjugates are administered to patients to provide an anti-angiogenic effect.

The invention relates to a biological adhesive for plywood and a preparation method thereof. The adhesive is a product obtained by chemically modifying animal blood protein grains with an amino compound and epoxy chloropropane, and the weight ratio of animal blood protein grains to amino compound to epoxy chloropropane is 10:1-5:1-5, wherein the animal blood protein grains are prepared from fresh animal blood, the grain size is greater than or equal to 50 meshes, and the solid content is 60-95 wt%; the amino compound is one or more than one of ammonia water, dimethylamine, diethylenetriamine, triethylenetetramine, polyvinylamine, polyethyleneimine and polyketoamine; and the fresh animal blood is blood of pigs, cows, sheep, chickens or ducks. The preparation method comprises the following steps of: chemically modifying the animal blood protein grains with the amino compound and epoxy chloropropane, and diluting the product to obtain the biological adhesive. The obtained adhesive reaches the bonding strength of No. I adhesives, the water resistance of an adhesive layer is increased, and the adhesive does not contain formaldehyde and has low cost and industrial popularization value.

The invention discloses pueraria root powder and a preparation method thereof. The pueraria root powder is characterized by comprising the following raw materials in percentage by weight: 40-60 percent of pueraria root powder, 10-30 percent of red Chinese date powder and 10-30 percent of carrot powder. The preparation method comprises the following steps: cleaning, peeling and slicing a pueraria root, superfine pulverizing and breaking wall of the pueraria root and drying the pueraria root by using hot air; carrying out cleaning, denucleating, slicing, color protection, vacuum freezing and drying and then superfine pulverizing on the red Chinese date; cleaning, slicing, preliminarily drying and then superfine pulverizing carrots and finally drying by hot air; and uniformly mixing the dried pueraria root powder, the red Chinese date powder and the carrot powder according to proper proportion and packaging to obtain the pueraria root powder. The invention has the functions of reducing pathogenic fire, neutralizing the effect of alcoholic drinks, enhancing the immunity, effectively reducing the serum cholesterol and enhancing the serum total protein and blood protein, traditional Chinese medicine values and health care efficacies of tonifying kidney and strengthening stomach, nourishing the blood and tranquilization and the like as well as the relieving function on nyctalopia.

Methods are described for improvement of the serum half life of therapeutic nucleic acids by 3′ conjugation to useful target proteins, or other large molecules with useful function. In one embodiment, a 3′ A, C or G overhang is added to ds-DNA and the primary amines conjugated using biocompatible bifunctional linkers to proteins. The resulting nucleic acid-3′-conjugates are serum nuclease-resistant and retained in vivo for long periods without rapid kidney clearance. Further, the choice of conjugate imparts additional functionality to the nucleic acid-3-conjugate. For example, if the protein in the DNA-protein conjugate is the first component of the complement cascade (Clq or Clqrs) and the DNA aptamer has been developed against surface components of a target cell, it can be used to treat bacterial or parasitic infections and cancers. If the protein is serum albumin or another common (nonimmunogenic) blood protein and the aptamer is directed against a toxin or venom, the aptamer-protein conjugate can be used as an antidote that binds and neutralizes the toxin or venom. Similar DNA (aptamer)-nanotube, -enzyme, and -toxin conjugates could also be used to target and selectively kill bacteria, parasites, and cancer cells in vivo. If the protein is an Fc antibody fragment or C3b protein from the complement system and the aptamer is developed against a bacterial cell capsular material, other cell surface component or viral cell surface component, then the aptamer-3′-protein conjugate can aid in opsonization of the target cells or viruses by phagocytic leukocytes.

A method and system for the extracorporeal treatment of blood to remove fluid from the fluid overloaded patient is disclosed that non-invasively measures osmotic pressure across a filter membrane of a blood filter. The filter is permeable to water and electrolytes, but not to blood protein. The osmotic pressure indicates the protein concentration in the blood. Osmotic pressure is used to detect when hypotension is about to occur in a patient, as a result of excessive blood volume reduction during treatment of the blood. Using the osmotic pressure measurement as a feedback signal, the rate of fluid extraction is automatically controlled to achieve the desired clinical outcome and avoid precipitating a hypotensive crisis in the patient.

A medical prosthetic device or medical implant containing a metal material (A) selected from the group consisting of titanium or an alloy thereof, zirconium or an alloy thereof, tantalum or an alloy thereof, hafnium or an alloy thereof, niobium or an alloy thereof and a chromium-vanadium alloy, wherein surface parts of the metal material (A) are coated with a layer of a corresponding hydride material (B) selected from titanium hydride, zirconium hydride, tantalum hydride, hafnium hydride, niobium hydride and chromium and / or vanadium hydride, respectively, said device or implant being characterised in that the layer of hydride material (B) comprises one or more biomolecule substances (C) associated therewith. The device or implant exhibits improved biocompatibility. The metal material (A) is preferably titanium. The biomolecule substance (C) may be selected from the following types of substances: Natural or recombinant bio-adhesives; natural or recombinant cell attachment factors; natural, recombinant or synthetic biopolymers; natural or recombinant blood proteins; natural or recombinant enzymes; natural or recombinant extracellular matrix proteins; natural or synthetic extracellular matrix biomolecules; natural or recombinant growth factors and hormones; natural, recombinant or synthetic peptide hormones; natural, recombinant or synthetic deoxyribonucleic acids; natural, recombinant or synthetic ribonucleic acids; natural or recombinant receptors; enzyme inhibitors; drugs; biologically active anions and cations; vitamins; adenosine monophosphate (AMP), adenosine diphosphate (ADP) or adenosine triphosphate (A TP); marker biomolecules; amino acids; fatty acids; nucleotides (RNA and DNA bases); and sugars.

The invention relates to a co-mixing film of ethylene-acetic acid ethylene copolymer and polysulfone. The co-mixing film comprises: 5 to 10 weight percent of polysulfone, 5 to 10 weight percent of ethylene-acetic acid ethylene copolymer, 5 to 10 weight percent of hole-forming agent and 70 to 75 weight percent of organic solvent. The preparation method comprises the following steps of: 1, mixing the raw materials in part by weight to prepare uniform spinning raw liquid, standing the raw liquid; 2, filtering the spinning raw liquid by a filter core with a hole diameter of 3 to 5 micrometers, and performing vacuumizing and debubbling to obtain film-forming liquid; and 3, coating the film-forming liquid on a support layer by a film scraper to obtain the co-mixing film after the solidification of the film-forming liquid. The co-mixing film prepared by the invention has the advantages of high removing rate, low blood protein and blood platelet absorption capacity, no or fewer heparins, simple preparation process, controlled preparation process, low cost, high application values and wide application fields.

The invention relates to a method using pancreatin-hydrolyzed swine blood corpuscle protein activated by swine fresh pancreas to produce swine blood protein peptide and haemoglobin, belonging to the field of feed additive. The invention takes fresh healthy swine blood corpuscle liquid as a raw material, pancreatin activated by swine fresh pancreas is hydrolyzed and filtered, the filtered supernatant is decolorized, then, the obtained protein liquid is dried to obtain the golden swine blood protein peptide, and the filter cake is dried to obtain the haemoglobin. The technical method has the following innovation points: 1, swine pancreas is taken as the raw material which is fresh and available, and the quality is controllable; 2, pancreatin activation method is simple, enzyme systems are rich, the activated enzyme has high activity, and the hydrolysis effect is good; 3, the swine fresh pancreatin has low cost, which is easy to carry out expanded production; 4, the swine blood corpuscle protein is hydrolyzed by pancreatin which can efficiently separate the haemoglobin thereof and can further prepare haemoglobin by drying the filter cake as the hydrolysate product, thus greatly improving the rate of multipurpose utilization of the swine blood corpuscle protein and avoiding resource waste.

It is intended to provide a blood purification membrane having excellent performance and showing little elution of blood and little adhesion of blood proteins or platelets. The above object can be achieved by using a moisten membrane, which is free from any membrane pore-sustaining agent and has a high water permeation dose and a large pore size, and lessening the pore size by drying the membrane after desolvation.

The invention belongs to the technical field of separation and extraction of bioactive substance and particularly relates to a method for preparing thrombin and pig blood protein hydrolysate respectively by taking blood plasma and blood corpuscles as a starting substrate after the anticoagulant treatment of fresh pig blood. The high-activity thrombin is prepared by the following steps of: freezing the blood plasma at low temperature; precipitating and collecting prothrombin; activating ions; purifying enzyme liquid and the like; and the high-activity pig blood protein hydrolysate is prepared by the following steps of: breaking the walls of the blood corpuscles; dissolving blood, performing segmental enzymolysis on complex enzyme; filtering and degerming and the like. The amino acid content of the pig blood protein hydrolysate prepared by the method accounts for over 80 percent of the protein, and the pig blood protein hydrolysate is easy to absorb and use. In the method, raw materialsare fully used and two high value-added products can be produced by feeding once. The whole production process saves high-toxicity organic solvents so as to overcome the defects of single product, solvent residues and the like and reduce production cost. By using the method, over 6,000U of thrombin competitive products and over 150g of high-activity pig blood protein hydrolysate powder can be prepared from1 L of pig blood.

Modified anti-angiogenic peptides are disclosed. The modified peptides are capable of forming a peptidase stabilized anti-angiogenic peptide. The modified anti-angiogenic peptides, particularly modified kringle 5 peptides are capable of forming a conjugate with a blood protein. Conjugates are prepared from anti-angiogenic peptides, particularly kringle 5 peptides, by combining the peptide with a reactive functional group with a blood protein. The conjugates may be formed in vivo or ex vivo. The conjugates are administered to patients to provide an anti-angiogenic effect.

The invention relates to a method for preparing high-F value pig blood oligopeptide. The high-F value oligopeptide is prepared by adopting fresh pig blood as the raw material, carrying out enzymolysis on pig blood protein by utilizing protease and adsorbing and removing the aromatic amino acid by active carbon. The method comprises selection of the protease and an enzymolysis technical parameter thereof, selection of an adsorbing agent and an adsorbing technical parameter thereof, and the like and aims to improve an additional value of pig blood, reduce environmental pollution and provide a new path for preparing the high-F value oligopeptide by the deep processing on the pig blood. The high-F value pig blood oligopeptide prepared by using the method has the molecular weight concentrated in 800-1,200Da, good balance of composition of amino acid and free amino acid, aromatic amino acid content being smaller than 0.1 percent, F value being larger than 25 and the product yield being larger than 10.74 percent.

The present invention provides an array for rapidly identifying a host cell population capable of producing a heterologous protein with improved yield and / or quality. The array comprises one or more host cell populations that have been genetically modified to increase the expression of one or more target genes involved in protein production, decrease the expression of one or more target genes involved in protein degradation, or both. One or more of the strains in the array may express the heterologous protein of interest in a periplasm compartment or may secrete the heterologous protein extracellularly through an outer cell wall. The strain arrays are useful for screening for improved expression of any protein of interest including therapeutic proteins, hormones, growth factors, extracellular receptors or ligands, proteases, kinases, blood proteins, chemokines, cytokines, antibodies and the like.

The invention discloses an extraction method of pig blood protein peptide. The extraction method comprises the following steps: steaming and cooking fresh pig blood used as a main raw material, mincing, adding water, adding proteinase for enzymolysis and adding flavourzyme for enzymolysis, inactivating enzyme, decolorizing, separating through a nanofiltration membrane, and performing spray drying to the obtained filtrate and obtain the pig blood protein peptide. The extraction method disclosed by the invention has the advantages of short production period, low cost, no environmental pollution and high product safety, and can be widely applied in the fields of health-care products, food, medicines and the like.

The present invention provides methods and compositions for producing heterologous protein with improved yield and / or quality. A library of randomized ribosomal binding site sequences is provided for the identification of a translation initiation region sequence optimal for expression of the heterologous protein. Also provided are novel ribosomal binding site sequences, and vectors and host cells having those sequences. The library of randomized sequences is useful for screening for improved expression of any protein of interest, including therapeutic proteins, hormones, a growth factors, extracellular receptors or ligands, proteases, kinases, blood proteins, chemokines, cytokines, antibodies and the like.

The invention provides a blood protein responsive type gamma-PGA (polyglutamic acid) hydrogel hemostasis material as well as a preparation method and an application thereof. The hemostasis material isprepared from a PHPA and DA (dopamine) molecule functionalized gamma-PGA polymer, a solvent with water as a main body, horseradish peroxidase and hydrogen peroxide, the synergetic enhancement effectof gamma-PGA, PHPA and DA on integration of wet high-strength wound is realized and the efficient blocking and hemostasis effect is achieved through Fe<3+> in gamma-PGA complexing blood, adsorption and blood coagulation of blood protein under the inducing action of benzene ring hydrophobic functional groups in PHPA and gel forming through oxidation and crosslinking by catechol groups in DA. The provided gamma-PGA hydrogel hemostasis material can effectively overcome the limitation of conventional pressing hemostasis method in application fields, besides, the problems that numerous hemostasis materials have poor blood responsiveness, poor integration capability for the wet bleeding wound and the like at present are solved, and the blood protein responsive type gamma-PGA hydrogel hemostasismaterial has the advantages of being high in hemostasis efficiency, good in biocompatibility, capable of allowing orthotopic injection of matched complicated wound types and the like and has broad market application prospects.

The present invention provides conjugates of disorazoles and their derivatives with cell-binding molecules, such as peptides, proteins, hormones, blood proteins and antibodies. The present invention further provides novel disorazole derivatives and processes of manufacturing such conjugates and disorazole derivatives. These compounds can be used as medicaments for the treatment of physiological and / or pathophysiological conditions in mammals, in particular for the treatment of various tumors.

The invention provides a method for selectively modifying a heparin structure by using biological enzyme, which can improve anticoagulation activity of heparin, reduce combination of heparin with blood protein such as platelet factors and the like, and reduce toxic and side effects. The invention belongs to the field of biological medicine. The antithrombus and anticoagulation activities of the heparin derivatives prepared by the method are 2 to 3 times higher than common heparin medicament, the 2-O-sulfate and 6-O-sulfate contents are about 20 percent of the common heparin, and the combination capability of the heparin derivatives with the platelet factors is about 20 percent of the common heparin. The novel heparin derivatives have high anticoagulation activity and low side effect.